ANI Pharmaceuticals ANIP Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $237.46M+20.5% | $247.06M+29.6% | $227.81M+53.6% | $211.37M+53.1% | $197.12M+43.4% | ||
| $93.58M+28.1% | $100.27M+24.9% | $93.39M+48.1% | $74.62M+29.3% | $73.04M+48.6% | ||
| $143.88M+16.0% | $146.79M+33.1% | $134.42M+57.7% | $136.76M+70.2% | $124.09M+40.6% | ||
| 60.6%-2.4pp | 59.4%+1.5pp | 59%+1.5pp | 64.7%+6.5pp | 62.9%-1.3pp | ||
| $10.6M+0.3% | $12.26M-26.3% | $12.3M+21.5% | $16.54M+127% | $10.56M+0.5% | ||
| $73.66M-3.8% | $82.79M+18.7% | $76.66M-3.1% | $81.77M+54.8% | $76.53M+59.4% | ||
| $198.57M+16.2% | $212.29M+8.9% | $191.57M+13.5% | $197.48M+48.6% | $170.93M+45.9% | ||
| $38.89M+48.5% | $34.77M— | $36.24M+277% | $13.89M+169% | $26.19M+29.0% | ||
| 16.4%+3.1pp | 14.1%— | 15.9%+29.7pp | 6.6%+2.8pp | 13.3%-1.5pp | ||
| -$3.77M+31.3% | -$4.41M+26.7% | -$4.73M-103% | -$5.44M-16.8% | -$5.48M-19.2% | ||
| -$651K-429% | $850K+162% | -$853K+66.4% | $1.74M+2,076% | $198K+719% | ||
| $40.22M+101% | $31.48M+329% | $33.8M+207% | $10.53M+560% | $19.99M-21.1% | ||
| $10.73M+149% | $3.99M+214% | $7.18M+198% | $1.98M— | $4.31M-39.6% | ||
| $29.49M+88.1% | $27.49M+368% | $26.62M+210% | $8.55M+474% | $15.68M-13.9% | ||
| 12.4%+4.5pp | 11.1%+16.5pp | 11.7%+28.0pp | 4%+5.7pp | 8%-5.3pp | ||
| $0-100% | $0-100% | $344K-15.3% | $407K0.0% | $406K0.0% | ||
| $1.28+85.5% | $1.17+313% | $1.13+189% | $0.36+357% | $0.69-15.9% | ||
| $1.31+87.1% | $1.24+325% | $1.19+194% | $0.37+364% | $0.70-16.7% | ||
| 21.5M+7.5% | 21.2M+9.9% | 21.1M+8.7% | 20.3M+5.1% | 20M+3.2% | ||
| 20.9M+6.7% | 20.1M+3.8% | 20.1M+3.5% | 19.8M+2.7% | 19.6M+2.7% | ||
| $5.75M+725% | $273K— | $3.14M+132% | $332K+112% | -$921K-110% | ||
| -$3.77M+31.3% | -$4.41M+26.7% | -$4.73M-103% | -$5.44M-16.8% | -$5.48M-19.2% | ||
| -$182K+98.5% | -$5.73M-203% | -$14.47M-1,854% | $1.28M+256% | -$12.09M-13,536% | ||
| -$651K-429% | $850K+162% | -$853K+66.4% | $1.74M+2,076% | $198K+719% | ||
| $237.46M+20.5% | $247.06M+29.6% | $227.81M+53.6% | $211.37M+53.1% | $197.12M+43.4% | ||
| $38.89M+48.5% | $34.77M+276% | $36.24M+277% | $13.89M+169% | $26.19M+29.0% | ||
| $59.81M+21.8% | $57.38M+1,933% | $58.87M+1,334% | $37.17M+87.1% | $49.09M+40.3% | ||
| $59.81M+21.8% | $57.38M+1,933% | $58.87M+1,334% | $37.17M+87.1% | $49.09M+40.3% | ||
| 25.2%+0.3pp | 23.2%+21.7pp | 25.8%+29.1pp | 17.6%+3.2pp | 24.9%-0.6pp | ||
| $38.89M+48.5% | $34.77M+276% | $36.24M+277% | $13.89M+169% | $26.19M+29.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are ANI Pharmaceuticals's profit margins?
- Gross margin is 60.8% and operating margin is 13.4%, with a 10.0% net margin.
- Where does ANI Pharmaceuticals's income statement data come from?
- Every line is extracted from ANI Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.